	AUDITORIUM SIRENE	NETTUNO 1-3	NETTUNO 4 SALA ECM	NETTUNO 5	NETTUNO 6	TRITONE	ULISSE	CAPRI		
14.00-14.30		Oral Communications	Oral Communications	Oral Communications	Oral Communications	Oral Communications	Oral Communications	Oral Communications		
14.30-15.00		RWE: Focus on DDI Studies and Medication Reconcialiation	Neurodegenerative Diseases I	Pharmacognosy I	Update from preclinical and clinical research	Cancer Pharmacology I	Cardiovascular and Metabolic Pharmacology	Immunopharmacology		
15.00-15.30		Reconcidiation								
15.30-16.00										
16.00-17.00	Opening Ceremony									
17.00-18.00	Plenary Lecture Advancing RNAi Therapeutics and the Importance of Being Unreasonable									
18.00-19.30	Round Table Opportunities and challenges in a changing regulatory landscape									
19.30-20.30		Welcome Cocktail								
21.00		Serata Giovani								

in Alzheimer's Disease: searching for new targets or new drugs? Is.30-16.00 * Symposium The evolution of drug R&D and pharmacology in the context of Al. start-ups and innovation districts Symposium Symposium The value of a topical pan-JAK inhibitor in the treatment of Chronic Hand Ezzema Symposium Symposium Symposium The value of a topical pan-JAK inhibitor in the treatment of Chronic Hand Ezzema Symposium Symposium Symposium The value of a topical pan-JAK inhibitor in the treatment of Chronic Hand Ezzema Symposium Symposium Symposium The value of a topical pan-JAK inhibitor in the treatment of Chronic Hand Ezzema Symposium Symposium The value of a topical pan-JAK inhibitor in the treatment of Chronic Hand Ezzema Symposium Symposium The value of a topical pan-JAK inhibitor in the treatment of Chronic Hand Ezzema Symposium Symposium The value of a topical pan-JAK inhibitor in the treatment of Chronic Hand Ezzema Symposium Symposium The value of a topical pan-JAK inhibitor in the treatment of Chronic Hand Ezzema Symposium Symposium The value of a topical pan-JAK inhibitor in the treatment of Chronic Hand Ezzema Symposium Symposium The value of a topical pan-JAK inhibitor in the treatment of Chronic Hand Ezzema Symposium Emerging players and fherapeutic strategies for LDL-C lowering and residual risk treatment in atherosclerosis joint Symposium SIF and SISA The use of Big Data in the lifecycle of medicines Oral Communications Oral Communications Oral Communications Symposium Emerging players and therapeutic strategies for LDL-C lowering and residual risk treatment in atherosclerosis joint Symposium SIF and SISA Symposium The evolution of drug R& Symposium Pharmacology and residual risk treatment in atherosclerosis joint Symposium SIF and SISA		ORIUM NETTUNG ENE 1-3	O NETTUNO 4 SALA ECM	NETTUNO 5	NETTUNO 6	TRITONE	ULISSE	CAPRI
pharmacology in the context of AI, start-ups and innovation districts Symposium Synaptic targets for Parkinson's disease could RWE and biomarkers make the difference? 16.30-17.00 * 17.30-18.00 Assemblea Gruppo ECPG Assemblea		Translational Phar in Alzheimer's D searching for targets	rmacology Disease: In new Symposium The evolution of	The dual challenge of immune system disorders: the case of vitiligo		Gene editing and	Beyond Molecules and Routes: Unveiling the True Value of	6
Assemblea Gruppo ECPG		or new drug	pharmacology	immunotherapies	properties of mediteranean	approaches for dyslipidemia and cardiovascular disorders Symposium Emerging players and therapeutic strategies for LDL-C lowering and residual risk treatment in atherosclerosis Joint Symposium SIF	Filamaceulicus	Symposium Medication review
Symposium Pharmacological bases of anticancer drug therapies 16.30-17.00 * 17.30-18.00 Assemblea Gruppo ECPG Oral Communications Neuropsycopharmacology 18.00-18.30 Neuropsycopharmacology Symposium Pharmacological bases of anticancer drug therapies Symposium Pharmacology In the use of Big Data in the lifecycle of medicines Oral Communications Pharmacogenetics Oral Communications Pharmacogenetics Symposium Emerging players and therapeutic strategies for LDL-C lowering and residual risk treatment in atherosclerosis Joint Symposium SIF and SISA Oral Communications Pharmacology of Oral Communications Pharmacology of Obesity and Metabolic Disorders I Symposium Translational approaches in leart failure and cardiometabolic disease	5.00 *		innovation	The value of a topical pan-JAK inhibitor in the treatment of Chronic				and deprescribing
17.30-18.00 Assemblea Gruppo ECPG Recommunications Neuropsycopharmacology Neuropsycopharmacology Wsymposium The use of Big Data in the lifecycle of medicines Oral Communications Pharmacogenetics Oral Communications Pharmacology of Obesity and Metabolic Disorders I Symposium Highlights in Ethnopharmacology Oral Communications Pharmacology of Obesity and Metabolic Disorders I	5.30 *	Synaptic targe	ets for Decision making isease in rare disease: could RWE and biomarkers make	aking ase: and make nace? Symposium Pharmacological bases of anticancer drug therapies ium Big ne of es	Highlights in		Biomarkers	Oral Communications Gender Pharmacology
17.30-18.00 Assemblea Gruppo ECPG Reprose Fig. 2	7.00 *		wSymposium					
17.30-18.00 Assemblea Gruppo ECPG 18.00-18.30 Assemblea Gruppo ECPG Assemblea Gruppo ECPG Assemblea Gruppo ECPG Oral Communications Neuropsycopharmacology Pharmacogenetics Oral Communications Pharmacology of Obesity and Metabolic Disorders I Symposium Translational approaches in heart failure and cardiometabolic disease	7.30 *		Data in the				Translational	Symposium Tools and techniques for didactic innovation + Collegio Nazionale
18.00–18.30 Pharmacogenetics of Obesity and Metabolic Disorders I cardiometabolic disease	Ass	nblea Communicat	medicines tions			Communications		
19.00-19.30	'		Tracology	Pharmacogenetics		of Obesity and Metabolic	cardiometabolic disease	Farmacologi Universitari (CNFU Assembly
	9.30							
19.30-20.00 Poster Session Cheese & Wine	0.00			Poster Session	Cheese & Wine			

Venerdì, 15 novembre 2024

	AUDITORIUM SIRENE	NETTUNO 1-3	NETTUNO 4 SALA ECM	NETTUNO 5	NETTUNO 6	TRITONE	ULISSE	CAPRI
14.30-15.00			Symposium Neurobiology of anorexia nervosa:	Symposium Digital Therapeutics:	Symposium Pharmacology in Neonates:			Symposium Current approache to the integration
5.00-15.30 *		Symposium Novel targets and novel mechanisms in immunopharmacology	preclinical and clinical evidence	next generation pharmacology	small size, huge challenges	SIF-Farmindustria Symposium Data Quality in scientific research: challenges and opportunities	Symposium Exploring novel pharmacological	of gender specific pharmacology in teaching
.5.30 - 16.00 *			Symposium Impact of chronic stress on the onset and progression of mental disorders: searching for novel pharmacological	Impact of chronic stress on the onset and progression of mental disorders: searching for novel pharmacological targets Symposium principles signaling in cancer and neurodegenerative	Symposium Beyond the Pandemic: the importance of vaccinations and the monitoring of their safety profile		approaches for chronic pain management	Oral Communications Overview on Antibiotics
.6.00-16.30 *		Symposium Spotlights on emerging approaches in immunopharmacology	targets		/ 1	Symposium Anti-inflammatory	Symposium Glymphatic system as a bridge connecting	& Antivirals
6.30-17.00 *			Symposium Purinergic signaling in cancer and neurodegenerative diseases: towards		Symposium Adaptogens and Immunomodulatory	drugs from naturally derived to synthetic molecules and back: the new frontiers of NSAIDs	pain, sleep disruption	
7.00-17.30 *					nications disorders			
17.30-18.00		Oral Communications	therapeutic approaches	Oral Communications RWE: Focus on		Oral	Oral Communications	Assemblea Sezione di Farmacologia Clinica
18.00-18.30		Cardiovascular and Pulmonary Pharmacology		Biologics		Communications Pharmacognosy II	Neuropharmacology II	Clinica
18.30-19.00								
19.00-19.30				SIF Gene	eral Assembly			
9.30-20.00								

CONGRESSO NAZIONALE DELLA SOCIETÀ ITALIANA DI FARMACOLOGIA SCIENCE TODAY FOR A BETTER SORRENTO (NA) 13-16 NOVEMBRE 2024

	AUDITORIUM SIRENE	NETTUNO 1-3	NETTUNO 4 SALA ECM	NETTUNO 5	NETTUNO 6	TRITONE	ULISSE	CAPRI
8.30-9.00			Oral Communications Inflammation		Oral Communications Gastrointestinal	Symposium Anticancer drug discovery		Oral Communications Pain Pharmacology
9.00-9.30		Symposium	Pharmacology I		Pharmacology	and preclinical development:	Symposium	Symposium The landscape of
9.30-10.00 *		Unravelling sex differences in cognition and behaviors for better		Symposium Clinical research: children on board	Symposium	methods and targets	How technology can accelerate drug development	
10.00-10.30 *		pharmacological treatments in neuropsychiatric disorders	degradation	bodia	Targeting the immune system to reduce cardiovascular	Symposium Oncology 3.0: new drugs and	Symposium Mechanism, efficacy and safety of medical	novel therapeutics i lysosomal storage diseases and alycogenoses: fron
10.30-11.00 *		Symposium	and respiratory diseases	Symposium The role of clinicians and	disease risk	technologies in oncogene- addicted solid tumors	devices made of substances: how to win the hurdle run	enzyme replaceme therapy to drug repurposing
11.00-11.30 *		Endocannabinoid signalling perturbations and neurodevelopmental traAjectories	Symposium Pulmonary Arterial Hypertension: state of the art and new	pharmacologists supporting AIFA drugs evaluation processes		Symposium Oncology trials: hot topics in	Symposium Novel targets for cardiometabolic	Symposium Therapeutic revolution: translate pharmacological innovation in tangible
11.30-12.00 *			signaling pathways			methodology	disorders	benefit for patients with Hemophilia A
12.00-12.15								
12.15-13.00	Plenary Lecture Gene therapy for drug-resistant temporal lobe epilepsy							
13.00-13.30								
13.30-14.00				Lunch/Poster	Session			

	AUDITORIUM SIRENE	NETTUNO 1-3	NETTUNO 4 SALA ECM	NETTUNO 5	NETTUNO 6	TRITONE	ULISSE	CAPRI
8.30-9.00		Oral Communications Pharmacology		Symposium New insights on the role of complement	Symposium Research and innovation approaches		Oral Communications	
9.00-9.30		of Obesity and Metabolic Disorders II	Symposium	in neurological diseases: from preclinic to clinic	to personalized pharmacotherapies for respiratory diseases		Rare Diseases and Orphan Drugs	Oral Communications
9.30-10.00 *		Symposium Targeting the interaction between gut microbiota, mucosa, and	Emerging trends in New Psychoactive Substances (NPS): From preclinical evidences to clinical perspectives	Lecture The first drug approved for Acanthamoeba Keratitis and its patients implications	Symposium Innovative solution in clinical pharmacogenomics:	Symposium Innovative pharmacological aspects of chronic heart failure therapy	Oral Communications Cancer	Neuropharmacology
10.00-10.30 *		neuro-immune system: a new hope in gastrointestinal pharmacotherapy		Symposium Role of complement in rare diseases	multi-omics data and one health approaches		Pharmacology II	Symposium The evolution of mutational
10.30-11.00 *						Symposium New possible		analysis in clinical, pharmacological
11.00-11.30 *		Symposium Biomarkers for	Symposium New frontiers in treating mental and addictive disorders: unveiling	and targeted therapies: facts and perspectives	Symposium	pharmacological targets for the treatment of eating disorders	Symposium Pharmaceuticals in the	and organizational aspects: opportunities and implications for the system
11.30-12.00 *		optimization of therapy of inflammatory bowel disease: from theory to practice	the therapeutic potential and mechanisms of hallucinogens	Lecture Benefit/risk profile of PI3K Inhibitors in rare non-oncological diseases: leniolisib in the APDS case	Antimicrobial stewardship: a new commitment for the clinical pharmacology	Lecture Medical needs and BMS research	environment: time to make use of what we already know and work towards what we need to know	
12.00-12.15								
12.15-13.00	Plenary Lecture Drug discovery across academic and industrial sectors: the value of collaboration							
13.00-13.30								
13.30-14.00				Lunch/Pos	ster Session			
14.00-14.30								

Sabato, 16 novembre 2024

	AUDITORIUM SIRENE	NETTUNO 1-3	NETTUNO 4 SALA ECM	NETTUNO 5	NETTUNO 6	TRITONE	ULISSE	CAPRI
8.30-9.00			Oral Communications RWE: New updates in onco-	Symposium Impact of drug	Oral Communications Pharmacology of	Oral Communications Overview of	Oral Communications	Oral Communications
9.00-9.30			hematology, pain management and diabetes	abuse on neurodevelopment trajectory: from molecular	Neurodegenerative Diseases II	Therapeutic Drug Monitoring	Pediatric Pharmacology	Inflammation Pharmacology II
9.30-10.00 *			Symposium	mechanisms to behavior	Symposium Pain and behavioural disturbances:	Symposium The pharmacology in the preclinical		Symposium Marine Pharmacology:
10.00-10.30 *			Novel drug candidates targeting phosphodiesterase (PDE) families 4 and 9 as an emerging strategy for cell survival and CNS diseases	Symposium The impact of environment on substance abuse vulnerability and progression	new pathogenetic insights for better pharmacological control	and clinical era of transgender medicine	Symposium Therapeutic applications of microvesicles and microparticles in the context of immunopharmacology	new opportunities for human health
10.30-11.00 *					Symposium Unmet medical needs in the management of tardive dyskinesia			
11.00-11.30 *								
11.30-12.00 *	Plenary lecture Endothelial cell lipid metabolism and vascular							
12.00-12.15	diseases							
12.15-13.00	Conclusions and Awards							

* OPEN COFFEE

SESSIONI SPONSORIZZATE

Segreteria Scientifica

Società Italiana di Farmacologia Via Giovanni Pascoli, 3 20129 Milano segreteria@sifweb.org Tel. +39 02-29520311 www.sifweb.org

Segreteria Organizzativa



PLANNING Congressi Srl Via Guelfa, 9 - 40138 Bologna (Italy) T +39 051 300100 (dir. 051 6037960) M +39 340 4571253 r.cantelli@planning.it www.planning.it